Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration to manufacture and market Abacavir tablets.

The tablets, which are ready for launch, are the generic equivalent of ViiV Healthcare Company’s Ziagen tablets.

The drug is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.

The annual sale of the product is approximately $88 million, the Hyderabad-based company said in a release on Tuesday.

(This article was published on December 18, 2012)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.